All In Biotech

Drug Trial Radar · NCT05451667

Single-Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of YJ001 in Healthy Volunteers

A Phase I, Randomized, Double-Blind, Placebo Controlled Single-Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Topical Application of YJ001 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Jan 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Aug 15, 2022

Primary completion

Dec 20, 2022

Study completion Dec 20, 2022

Sponsor

Sponsor type
Industry
Collaborators
Zhejiang Yuejia Pharmaceuticals Co., Ltd.
First posted
Jul 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This phase I, randomized, double-blind, placebo controlled study is to investigate the safety, tolerability and pharmacokinetics (PK) of topically administered YJ001 in a single-ascending dose (SAD) fashion in healthy volunteers between 18 to 55 years of age, to establish the dosage range for spray use, and to provide a dosage regimen for Phase I multiple-ascending dose (MAD) study in healthy subjects. The study is to enroll 4 cohorts, the doses of which are 148, 296, 552 and 828 mg, with the option to enroll 2 additional cohorts (8 subjects for each cohort) without requiring a protocol amendment. Subjects will be screened between Day -28 and Day -2 and will be admitted to the clinic on Day -1. Subjects will be housed within the clinic from Day -1 through Day 8 and will be discharged on Day 8 after all scheduled study procedures have been completed.

Conditions

  • Safety and Tolerability

Interventions

  • YJ001 for Spray UseDrug

    YJ001 (active ingredient)

  • Placebo of YJ001 for Spray UseDrug

    Hydroxypropyl Methylcellulose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events and significant laboratory abnormalityTime frame: Day -28 to Day 8
  2. Systemic exposure of the 4 analytes to be assayedTime frame: Day 1 to Day 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pharmaron CPC, Inc.

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.